Loading quotes...

Forecast

The analysts' average price target is €69.95 (+0.29%). The median is €69.69 (-0.09%).

Buy	16
Hold	9
Sell	0

News Go to news feed

Ashland Global to release quarterly results on November 3 and analysts expect significantly higher profit

Ashland Global will publish results for the quarter ended September 30, 2026, on November 3, 2026. On average, 10 analysts expect earnings of $1.27 per share (prior year $0.710) and revenue of $501.8 million (prior year $478.0 million, +4.97%). For the just-completed fiscal year, analysts forecast average earnings of $3.50 per share versus -$18.230 in the prior year and revenue of about $1.87 billion (prior year $1.82 billion). » More on finanzen.net
Ashland brings Permexa sodium caprate to market for oral peptide and biologic drugs

Ashland has announced the commercial launch of Permexa sodium caprate, an intestinal permeation enhancer for oral peptide and biologic medicines as well as poorly permeable active ingredients. The excipient is intended to improve formulation consistency, powder flow, compressibility and tablet scalability while retaining permeation‑enhancing properties. Before the rollout, Ashland collaborated globally with pharma companies, biotech firms and CDMOs and sees synergies with its existing vinylpyrrolidone portfolio; additional products are in the pipeline. » More on de.investing.com
Ashland considers sale after takeover interest

Shares of Ashland rose about 5.5% after reports said the specialty chemicals company is reviewing a possible sale. Ashland is working with Citigroup and Lazard and is in contact with both strategic and financial bidders, including Advent, Apollo, Carlyle and Standard Investments. Discussions are ongoing and it is unclear whether they will lead to a transaction; previously, activist investor Ancora had pushed for a sale and secured measures to strengthen capital allocation. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Ashland LLC has already paid €1.08 in dividends. The last payout was in September.

Financials

In the last quarter, Ashland LLC had revenue of €439.66m and net profit of -€14.13m

(EUR)	September 2026	YoY
Revenue	439.66m	7.94%
Gross profit	158.03m	16.64%
Net profit	-14.13m	151.80%
EBITDA	66.21m	40.23%

Fundamentals

Metric	Value
Market capitalization	€3.13bn
Number of shares	45.79m
52-week high/low	€69.91 - €42.88
Dividend yield	2.10%
Dividends TTM	€1.44
Beta	0.36
P/E ratio	849.50
PEG ratio	-10.47
P/B ratio	1.90
P/S ratio	1.88

Company profile

Ashland Global Holdings Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. The Intermediates and Solvents segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. Ashland Global Holdings Inc. offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Inc. and changed its name to Ashland Global Holdings Inc. in September 2016. Ashland Global Holdings Inc. was founded in 1924 and is based in Wilmington, Delaware.

Name	Ashland LLC
CEO	Guillermo Novo
Headquarters	Wilmington, de USA
Website	ashland.com
Sector	Energy
Industry	Energy Equipment & Services
IPO	17/03/1980
Employees	2,900